Gaza Medical Support: Plea to US Medical Community
ozempic and Cardiovascular Risk: New findings Demand Closer Scrutiny
What Happened? A Closer Look at the SELECT Trial
A major clinical trial, the SELECT trial, has revealed a potential increased risk of cardiovascular events – including heart attack, stroke, and cardiovascular death – in individuals with obesity and established cardiovascular disease who were treated with semaglutide (Ozempic). The study, involving over 17,600 participants, showed a statistically significant, though relatively small, increase in thes events compared to a placebo group. This finding challenges previous assumptions about the cardiovascular safety of GLP-1 receptor agonists like semaglutide.
understanding the SELECT Trial: Key Details
The SELECT trial specifically focused on adults with obesity (BMI of 30 or higher) *and* pre-existing cardiovascular disease, such as heart attack, stroke, or peripheral artery disease. participants were randomly assigned to receive either 2.4 mg of semaglutide weekly or a placebo, in addition to their standard cardiovascular care. The primary outcome was the first occurrence of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or unstable angina requiring hospitalization. Over an average of 3.4 years, the semaglutide group experienced a 15% increased risk of these events.
| Outcome | Semaglutide Group (n=8831) | Placebo Group (n=8801) | Hazard Ratio (95% CI) |
|---|---|---|---|
| Cardiovascular Death | 3.7% | 2.1% | 1.74 (1.11 to 2.73) |
| Nonfatal Myocardial Infarction | 2.6% | 1.9% | 1.33 (0.83 to 2.13) |
| Nonfatal stroke | 3.7% | 3.0% | 1.22 (0.80 to 1.85) |
| Unstable Angina Requiring Hospitalization | 1.2% | 0.8% | 1.48 (0.76 to 2.88) |
What Does This mean? Beyond the headlines
The increased risk, while statistically significant, is significant to contextualize. The absolute risk difference was relatively small – approximately 1.7% over the study period. However, for individuals already vulnerable due to existing heart disease, even a small increase in risk is concerning. The findings suggest that semaglutide may not be universally cardioprotective,and its use in this specific population requires careful consideration.
Who is Affected? Identifying At-Risk Individuals